Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action (Q34544845)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Nicholas J. Vogelzang

3

object named as

Nicholas J Vogelzang

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Michael A. Carducci

9

object named as

Michael A Carducci

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

Mario A Eisenberger

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Menachem Laufer

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Oliver Sartor

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Donald Thornton

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Blake Lee Neubauer

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Victoria Sinibaldi

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Gary Lieskovsky

8

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Mariana Zahurak

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Derek Raghavan

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

0 references

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

114-119

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

STUDIES ON PROSTATIC CANCER

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Discovery of the role of dihydrotestosterone in androgen action.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Pharmacokinetic parameters and mechanisms of inhibition of rat type 1 and 2 steroid 5alpha-reductases: determinants for different in vivo activities of GI198745 and finasteride in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Treatment with finasteride following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Combined finasteride and flutamide therapy in men with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

5 alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Fetal Death in Mice Lacking 5 -Reductase Type 1 Caused by Estrogen Excess

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

The development of androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.08.017

7 January 2021

Identifiers

10.1016/J.UROLOGY.2003.08.017

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34544845&oldid=2201567446"